Affinity DataIC50: 11nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 ...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 ...More data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 ...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 35nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 41nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 50nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 51nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/...More data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 63nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 75nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 92nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 170nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 180nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 230nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 240nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 290nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 300nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2....More data for this Ligand-Target Pair
Affinity DataIC50: 320nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 320nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 350nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 500nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 610nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 620nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2....More data for this Ligand-Target Pair
Affinity DataIC50: 630nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 740nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00...More data for this Ligand-Target Pair
Affinity DataIC50: 830nMAssay Description:Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2....More data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluoro...More data for this Ligand-Target Pair